Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC.RVPH · Entity 8147 | Director · President and CEO | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2036-03-17 | Direct | 109,150 |
Reported balance
After 2026-03-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 109,150 · Balance 109,150 F1: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2036-03-17 | IndirectBy Spouse | 40,925 |
Reported balance
After 2026-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-18 · Grant · Acquired 40,925 · Balance 40,925 F2: This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
F2: This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 17:00 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 40,925 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001437749-26-009258 · rdgdoc.xml · derivative · entry 2 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 40,925 Underlying: Common Stock, par value $0.0001 per share · 40,925 shares Expires 2036-03-17 F2 · kind: This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. F2 · derivative.exercise_date: This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 17:00 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 109,150 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001437749-26-009258 · rdgdoc.xml · derivative · entry 1 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,150 Underlying: Common Stock, par value $0.0001 per share · 109,150 shares Expires 2036-03-17 F1 · kind: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. F1 · derivative.exercise_date: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 16:30 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 181,500 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001437749-25-004220 · rdgdoc.xml · derivative · entry 2 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 181,500 Underlying: Common Stock, par value $0.0001 per share · 181,500 shares Expires 2035-02-12 F2 · kind: This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows: (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. F2 · derivative.exercise_date: This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows: (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 16:30 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 519,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001437749-25-004220 · rdgdoc.xml · derivative · entry 1 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,000 Underlying: Common Stock, par value $0.0001 per share · 519,000 shares Expires 2035-02-12 F1 · kind: This option award was made on February 13, 2025 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. F1 · derivative.exercise_date: This option award was made on February 13, 2025 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 17:01 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 77,843 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001437749-24-029388 · rdgdoc.xml · derivative · entry 2 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 77,843 Underlying: Common Stock, par value $0.0001 per share · 77,843 shares Expires 2034-09-14 F2 · kind: Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan. F2 · derivative.exercise_date: Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 17:01 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 158,451 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001437749-24-029388 · rdgdoc.xml · derivative · entry 1 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,451 Underlying: Common Stock, par value $0.0001 per share · 158,451 shares Expires 2034-09-14 F1 · kind: Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee (the "Compensation Committee") on September 15, 2024 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan. F1 · derivative.exercise_date: Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee (the "Compensation Committee") on September 15, 2024 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 16:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.74 | $0.00 |
DisclosureSEC source: 0001437749-23-011381 · rdgdoc.xml · derivative · entry 2 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 150,000 Underlying: Common Stock, par value $0.0001 per share · 150,000 shares Expires 2033-04-24 F2 · derivative.exercise_date: Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the 2020 Plan. The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 16:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 443,000 | $0.00 Strike: $6.74 | $0.00 |
DisclosureSEC source: 0001437749-23-011381 · rdgdoc.xml · derivative · entry 1 Bhat Laxminarayan · CIK 0001818245 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,000 Underlying: Common Stock, par value $0.0001 per share · 443,000 shares Expires 2033-04-24 F1 · derivative.exercise_date: Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.